Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
27 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
CytoTools AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'CytoTools AG - Product Pipeline Review - 2014', provides an overview of the CytoTools AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of CytoTools AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of CytoTools AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of CytoTools AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the CytoTools AG's pipeline products Reasons to buy - Evaluate CytoTools AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of CytoTools AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the CytoTools AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of CytoTools AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of CytoTools AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of CytoTools AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 CytoTools AG Snapshot 4 CytoTools AG Overview 4 Key Information 4 Key Facts 4 CytoTools AG - Research and Development Overview 5 Key Therapeutic Areas 5 CytoTools AG - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 CytoTools AG - Pipeline Products Glance 9 CytoTools AG - Late Stage Pipeline Products 9 Pre-Registration Products/Combination Treatment Modalities 9 Phase III Products/Combination Treatment Modalities 10 CytoTools AG - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 CytoTools AG - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 CytoTools AG - Drug Profiles 14 DermaPro CL-05 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Peptid 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 HMW-02Ak 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 HMW-02Ap 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 LMW-0x 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CytoTools AG - Pipeline Analysis 20 CytoTools AG - Pipeline Products by Route of Administration 20 CytoTools AG - Pipeline Products by Molecule Type 21 CytoTools AG - Recent Pipeline Updates 22 CytoTools AG - Dormant Projects 24 CytoTools AG - Locations And Subsidiaries 25 Head Office 25 Appendix 26 Methodology 26 Coverage 26 Secondary Research 26 Primary Research 26 Expert Panel Validation 26 Contact Us 27 Disclaimer 27
List of Tables CytoTools AG, Key Information 4 CytoTools AG, Key Facts 4 CytoTools AG - Pipeline by Indication, 2014 6 CytoTools AG - Pipeline by Stage of Development, 2014 7 CytoTools AG - Monotherapy Products in Pipeline, 2014 8 CytoTools AG - Pre-Registration, 2014 9 CytoTools AG - Phase III, 2014 10 CytoTools AG - Phase II, 2014 11 CytoTools AG - Phase I, 2014 12 CytoTools AG - Preclinical, 2014 13 CytoTools AG - Pipeline by Route of Administration, 2014 20 CytoTools AG - Pipeline by Molecule Type, 2014 21 CytoTools AG - Recent Pipeline Updates, 2014 22 CytoTools AG - Dormant Developmental Projects,2014 24
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.